Lorlatinib

Chemical formula: C₂₁H₁₉FN₆O₂  Molecular mass: 406.421 g/mol  PubChem compound: 71731823

Therapeutic indications

Lorlatinib is indicated for:

Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-positive

Population group: only adults (18 - 65 years old)

Lorlatinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Lorlatinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:

  • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
  • crizotinib and at least one other ALK TKI.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lorlatinib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

CYP3A4/5 strong inducers

at least one of
Strong potency CYP3A4 inducers
Cytochrome P-450 CYP3A5 strong inducers

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: LORVIQUA Film-coated tablet
Structured Product Labeling (SPL/PLR) 2021: LORBRENA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈